Becker's Healthcare January 15, 2025
Alexandra Murphy

A new report from HHS’ Office of Inspector General raises concerns about the FDA’s accelerated approval process for drugs with weak supporting evidence, Bloomberg reported Jan. 14.

The report highlights issues with the approvals of Biogen’s Alzheimer treatment, Aduhelm; Serepta Therapeutics’ Duchenne muscular dystrophy therapy, Exondys 51; and Covis Pharma’s preterm birth prevention treatment, Makena.

The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, OIG, Survey / Study, Trends
Related Articles:
Opinion: STAT+: How the FDA and CMS worked together on a new approach to paying for digital mental health treatments
FDA's health kick: New food labels, banned food dyes, and more
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
What A Potential FDA Red Dye No. 3 Ban Could Mean For Public Health
STAT+: Former Trump FDA, CMS heads lay out how his return could reshape health policy

Share This Article